Montiva

Montelukast
4 mg Oroflash Tablet, 5 mg Oroflash Tablet & 10 mg Tablet
Description:

Montelukast is a selective and orally active competitive cysteinyl leukotriene receptor antagonist, that inhibits the cysteinyl leukotriene (CysLT1) receptor to occupy the receptor. The cysteinyl leukotriene (CysLT1) receptor is found in the human airway with which cysteinyl leukotrienes bind to cause edema and smooth muscle contraction. Cysteinyl leukotrienes (CysLTs) have been correlated with the pathophysiology of asthma and allergic rhinitis.


  • Composition

    Montiva 4 Tablet : Each Oroflash tablet contains Montelukast Sodium BP equivalent to Montelukast 4 mg.

    Montiva 5 Tablet : Each Oroflash tablet contains Montelukast Sodium BP equivalent to Montelukast 5 mg.

    Montiva 10 Tablet : Each film coated tablet contains Montelukast Sodium BP equivalent to Montelukast 10 mg.
  • Indication

    Montelukast is indicated for the prophylaxis and chronic treatment of asthma, exercise-induced bronchoconstriction (EIB) and seasonal allergic rhinitis.
  • Dosage & Administration

    For adults and adolescents (15 years of age and older): 10 mg tablet once daily in the evening.

    Children 6-14 years: 5 mg Oroflash tablet once daily in the evening.
  • Contraindication

    Montelukast is contraindicated to patients with hypersensitivity to any component of this product.
  • Precaution

    Montelukast is not indicated for use in the reversal of bronchospasm in acute asthma attacks. Montelukast should not be abruptly substituted for inhaled or oral corticosteroids. Patients with known aspirin sensitivity should continue avoidance of aspirin or non-steroidal anti-inflammatory agents while taking Montelukast. Patients should be alert for neuropsychiatric events. Physician should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications presenting in their patients.
  • Side Effects

    Generally, Montelukast is well-tolerated. Side effects include fever, headache, cough, abdominal pain, diarrhea, otitis media, influenza, rhinorrhea, upper respiratory tract infection.
  • Drug Interaction

    Montelukast has been administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma. In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following medical products: theophylline, prednisolone, prednisone, oral contraceptives, terfenadine, digoxin and warfarin.
  • Overdose

  • Pregnancy & Lactation

    In Pregnancy: Montelukast is a pregnancy category B drug .There is no adequate and well-controlled studies in pregnant women. Montelukast should be used during pregnancy only if clearly needed.

    In Lactation: It is not known if Montelukast is excreted in human milk. Caution should be exercised when Montelukast is given to a nursing mother.
  • Storage Condition

    Keep in dry place away from light and heat. Keep out of the reach of children.
  • How Supplied

    Montiva 4 Tablet : Each box contains 30 tablet in Alu-Alu blister pack.

    Montiva 5 Tablet : Each box contains 30 tablet in Alu-Alu blister pack.

    Montiva 10 Tablet : Each box contains 30 tablet in Alu-Alu blister pack.